Cipla Ltd.

BSE: 500087 | NSE: CIPLA
Large Cap | Pharmaceuticals & Drugs
1426.80
-11.95 (-0.83%)
< Home < Back

USFDA conducts routine cGMP inspection at manufacturing facility of Cipla’s arm

Date: 03-05-2023

The United States Food and Drug Administration (USFDA) has conducted a routine current Good Manufacturing Practices (cGMP) inspection at the manufacturing facility of InvaGen Pharmaceuticals Inc., wholly owned subsidiary of Cipla, located in Fall River, Massachusetts, USA, from April 24, 2023 to May 1, 2023. The inspection concluded with zero Form 483 observations.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.